Network meta-analysis for efficacy and safety of TACE combined with anti-angiogenic drugs in the treatment of unresectable primary liver cancer
- VernacularTitle:TACE联合抗血管生成药治疗不可切除PLC有效性和安全性的网状Meta分析
- Author:
Fenping LU
1
,
2
;
Guangyan XING
1
,
2
;
Bowen LIU
1
,
2
;
Xiaobin LI
1
,
2
;
Kai ZHAO
3
;
Yun RAN
1
;
Fenfang WU
1
;
Shiping HU
1
Author Information
1. Shenzhen Hospital，Beijing University of Chinese Medicine，Guangdong Shenzhen 518172，China
2. Beijing University of Chinese Medicine，Beijing 100029，China
3. Dept. of Nephrology，Shaanxi Sunshine Chinese Medical Hospital for Liver and Kidney Disease，Xi’an 710016，China
- Publication Type:Journal Article
- Keywords:
primary liver cancer;
unresectable;
transcatheter
- From:
China Pharmacy
2024;35(20):2533-2540
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically evaluate the efficacy and safety of transcatheter arterial chemoembolization （TACE） combined with anti-angiogenic drugs for the treatment of unresectable primary liver cancer （PLC）. METHODS Retrieved from Chinese and English databases such as CNKI， the Cochrane Library， Google， and Baidu Academic， randomized controlled trial （RCT） about TACE combined with anti-angiogenic drugs for the treatment of unresectable PLC were collected from the inception to May 27， 2024. After screening the literature， extracting data， and evaluating the quality of the literature， network meta-analysis was performed using R 4.2.2 and Stata 17.0. RESULTS A total of 44 RCT were included， involving 5 607 patients and 8 interventions. The network meta-analysis results showed that for prolonging median overall survival （mOS） and median progression- free survival （mPFS）， TACE+apatinib had the best efficacy， with TACE+apatinib and TACE+sorafenib ranking as the top two. For improving objective response rate （ORR） and disease control rate （DCR）， TACE+donafenib had the best efficacy， with TACE+ donafenib and TACE+ lenvatinib ranking as the top two. In terms of safety， TACE+donafenib was the best， with TACE+donafenib and TACE+apatinib ranking as the top two. CONCLUSIONS TACE+apatinib and TACE+donafenib have good efficacy for patients with unresectable PLC， and TACE+donafenib has the best safety profile.
